Form Approved
OMB No. 0920-0666
Exp. Date: 12/31/2026
www.cdc.gov/nhsn

NHSN
NATIONAL HEALTHCARE SAFETY NETWORK

Hemovigilance Module
Monthly Reporting Denominators

***Required for saving**

*Facility ID#: _____ *Month: _____ *Year: _____

Table 1

Products			*Units Transfused	*Aliquots Transfused	*Total Discards
Whole Blood		**TOTAL**			
Red blood cells		**TOTAL**			
	Whole blood derived	Not irradiated or leukocyte reduced			
		Irradiated			
		Leukocyte reduced			
		Irradiated and leukocyte reduced			
	Apheresis	**TOTAL**			
		Not irradiated or leukocyte reduced			
		Irradiated			
		Leukocyte reduced			
		Irradiated and leukocyte reduced			
Platelets		**TOTAL**			
	Whole blood derived	Not irradiated or leukocyte reduced			
		Irradiated			
		Leukocyte reduced			
		Irradiated and leukocyte reduced			
	Apheresis	**TOTAL**			
		Not irradiated or leukocyte reduced			
		Irradiated			
		Leukocyte reduced			
		Irradiated and leukocyte reduced			
Plasma (all types)	Total whole blood derived				
	Total apheresis				
Cryoprecipitate					

Form Approved
OMB No. 0920-0666
Exp. Date: 12/31/2026
www.cdc.gov/nhsn

NHSN
NATIONAL HEALTHCARE SAFETY NETWORK

Hemovigilance Module
Monthly Reporting Denominators

*Does your facility transfuse blood products treated with pathogen reduction technology? _____ Yes _____ No
^If yes, then complete Table 2.

Table 2

Products			Units Transfused	Aliquots Transfused	Total Discards
Red blood cells	Whole blood derived	TOTAL			
		S-303-treated			
		Riboflavin-treated			
	Apheresis	TOTAL			
		S-303 -treated			
		Riboflavin-treated			
Platelets	Whole blood derived	TOTAL			
		Psoralen-treated			
		Riboflavin-treated			
	Apheresis	TOTAL			
		Psoralen-treated			
		Riboflavin-treated			
Plasma (all types)	Whole blood derived	TOTAL			
		Psoralen-treated			
		Riboflavin-treated			
	Apheresis	TOTAL			
		Psoralen-treated			
		Riboflavin-treated			
Cryoprecipitate		TOTAL			
		Psoralen-treated			
		Riboflavin-treated			
		Pathogen Reduction Cryoprecipitated Fibrinogen Complex			

^If your facility transfused pathogen reduced apheresis platelets (e.g., the apheresis platelet total in table 2 is greater than 0), then complete Table 3.

Table 3

Products			Units Transfused	Aliquots Transfused	Total Discards
Platelets	Apheresis	Psoralen-treated			
		Psoralen-treated and in Plasma			
		Psoralen-treated and in Platelet additive solution			
		Riboflavin-treated			
		Riboflavin-treated and in Plasma			
		Riboflavin-treated and in Platelet additive solution			

*Patient samples collected for type and screen or crossmatch: _____

*Total crossmatch procedures: _____

Total patients transfused: _____

Form Approved
OMB No. 0920-0666
Exp. Date: 12/31/2026
www.cdc.gov/nhsn

NHSN
NATIONAL HEALTHCARE SAFETY NETWORK

Hemovigilance Module
Monthly Reporting Denominators

Custom Fields	
Label	Label
_____ _____	_____ _____
_____ _____	_____ _____
_____ _____	_____ _____
_____ _____	_____ _____